Transient receptor potential vanilloid type 1: cardioprotective effects in diabetic models

References

• Fernandez-Twinn DS, Hjort L, Novakovic B, et al. Intrauterine programming of obesity and type 2 diabetes. Diabetologia. 2019;62(10):1789–18. doi: 10.1007/s00125-019-4951-9
   PubMed Web of Science ®Google Scholar
• Strain WD, Paldánius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol. 2018;17(1):57. doi: 10.1186/s12933-018-0703-2
   PubMed Web of Science ®Google Scholar
• Liu Z, Fu C, Wang W, et al. Prevalence of chronic complications of type 2 diabetes mellitus in outpatients - a cross-sectional hospital based survey in urban China. Health Qual Life Outcomes. 2010;8(1):62. doi: 10.1186/1477-7525-8-62
   PubMed Web of Science ®Google Scholar
• Seferović PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(27):1718–1727. doi: 10.1093/eurheartj/ehv134
   PubMed Web of Science ®Google Scholar
• Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974;34(1):29–34. doi: 10.1016/0002-9149(74)90089-7
   PubMed Web of Science ®Google Scholar
• Matsue Y, Suzuki M, Nakamura R, et al. Prevalence and prognostic implications of pre-diabetic state in patients with heart failure. Circ J. 2011;75(12):2833–2839. doi: 10.1253/circj.CJ-11-0754
   PubMed Web of Science ®Google Scholar
• Gustafsson I, Brendorp B, Seibæk M, et al. Influence of diabetes and diabetes-gender interaction on the risk of death in patients hospitalized with congestive heart failure. J Am Coll Cardiol. 2004;43(5):771–777. doi: 10.1016/j.jacc.2003.11.024
   PubMed Web of Science ®Google Scholar
• Miki T, Yuda S, Kouzu H, et al. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev. 2013;18(2):149–166. doi: 10.1007/s10741-012-9313-3
   PubMed Web of Science ®Google Scholar
• Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27(8):1879–1884. doi: 10.2337/diacare.27.8.1879
   PubMed Web of Science ®Google Scholar
• Rubler S, Dlugash J, Yuceoglu YZ, et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30(6):595–602. doi: 10.1016/0002-9149(72)90595-4
   PubMed Web of Science ®Google Scholar
• Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–638. doi: 10.1161/CIRCRESAHA.117.311586
   PubMed Web of Science ®Google Scholar
• Nakamura M, Sadoshima J. Cardiomyopathy in obesity, insulin resistance and diabetes. Journal Of Physiology. 2020;598(14):2977–2993. doi: 10.1113/JP276747
   PubMed Web of Science ®Google Scholar
• Penpargkul S, Fein F, Sonnenblick, EH, et al. Depressed cardiac sarcoplasmic reticular function from diabetic rats. J Mol Cell Cardiol. 1981;13(3):303–309. doi: 10.1016/0022-2828(81)90318-7
   PubMed Web of Science ®Google Scholar
• Trost SU, Belke DD, Bluhm WF, et al. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes. 2002;51(4):1166–1171. doi: 10.2337/diabetes.51.4.1166
   PubMed Web of Science ®Google Scholar
• Westermeier F, Riquelme JA, Pavez M, et al. New molecular insights of insulin in diabetic cardiomyopathy. Front Physiol. 2016;7:125. doi: 10.3389/fphys.2016.00125
   PubMed Web of Science ®Google Scholar
• Ritchie RH, Abel ED. Basic mechanisms of diabetic heart disease. Circ Res. 2020;126(11):1501–1525. doi: 10.1161/CIRCRESAHA.120.315913
   PubMed Web of Science ®Google Scholar
• Cai L, Kang YJ. Cell death and diabetic cardiomyopathy. Cardiovasc Toxicol. 2003;3(3):219–228. doi: 10.1385/CT:3:3:219
   PubMedGoogle Scholar
• Jia G, DeMarco VG, Sowers JR. Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy. Nat Rev Endocrinol. 2016;12(3):144–153. doi: 10.1038/nrendo.2015.216
   PubMed Web of Science ®Google Scholar
• Boyer JK, Thanigaraj S, Schechtman KB, et al. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus. Am J Cardiol. 2004;93(7):870–875. doi: 10.1016/j.amjcard.2003.12.026
   PubMed Web of Science ®Google Scholar
• Zabalgoitia M, Ismaeil MF, Anderson L, et al. Prevalence of diastolic dysfunction in normotensive, asymptomatic patients with well-controlled type 2 diabetes mellitus. Am J Cardiol. 2001;87(3):320–323. doi: 10.1016/S0002-9149(00)01366-7
   PubMed Web of Science ®Google Scholar
• Cherney DZ, Odutayo A, Aronson R, et al. Sodium glucose cotransporter-2 inhibition and cardiorenal protection: JACC review Topic of the Week. J Am Coll Cardiol. 2019;74(20):2511–2524. doi: 10.1016/j.jacc.2019.09.022
   PubMed Web of Science ®Google Scholar
• Joubert M, Jagu B, Montaigne D, et al. The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model. Diabetes. 2017;66(4):1030–1040. doi: 10.2337/db16-0733
   PubMed Web of Science ®Google Scholar
• Qin S-L, Liu S-L, Wang R-R. [Protective effect of capsaicin on against myocardial ischemia-reperfusion injury of rat in vivo]. Sichuan Da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Med Sci Ed. 2008;39(4):550–554.
   Google Scholar
• Szallasi A, Cortright DN, Blum CA, et al. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov. 2007;6(5):357–372. doi: 10.1038/nrd2280
   PubMed Web of Science ®Google Scholar
• Tominaga M, Tominaga T. Structure and function of TRPV1. Pflugers Archiv. European J Physiology. 2005;451(1):143–150. doi: 10.1007/s00424-005-1457-8
   Google Scholar
• Premkumar LS, Abooj M. TRP channels and analgesia. Life Sci. 2013;92(8–9):415–424. doi: 10.1016/j.lfs.2012.08.010
   PubMed Web of Science ®Google Scholar
• Li L, Chen C, Chiang C, et al. The impact of TRPV1 on cancer pathogenesis and therapy: a systematic review. Int J Biol Sci. 2021;17(8):2034–2049. doi: 10.7150/ijbs.59918
   PubMed Web of Science ®Google Scholar
• Zhang C, Ye L, Zhang Q, et al. The role of TRPV1 channels in atherosclerosis. channels (Austin, Tex. Channels. 2020;14(1):141–150. doi: 10.1080/19336950.2020.1747803
   PubMed Web of Science ®Google Scholar
• Hurt CM, Lu Y, Stary M, et al. Transient Receptor Potential Vanilloid 1 Regulates Mitochondrial Membrane Potential and Myocardial Reperfusion Injury. J Am Heart Assoc. 2016;5(9). doi: 10.1161/JAHA.116.003774
   PubMed Web of Science ®Google Scholar
• Yoshie K, Rajendran, PS, Massoud L, et al. Cardiac TRPV1 afferent signaling promotes arrhythmogenic ventricular remodeling after myocardial infarction. JCI Insight. 2020;5(3). doi: 10.1172/jci.insight.124477
   PubMed Web of Science ®Google Scholar
• Zahner MR, Li D-P, Chen S-R, et al. Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats. Journal Of Physiology. 2003;551(2):515–523. doi: 10.1113/jphysiol.2003.048207
   PubMed Web of Science ®Google Scholar
• Hoebart C, Rojas‐Galvan, NS, Ciotu, CI, et al. No functional TRPA1 in cardiomyocytes. Acta Physiol (Oxf). 2021;232(4):e13659. doi: 10.1111/apha.13659
   PubMed Web of Science ®Google Scholar
• Hong J, Lisco AM, Rudebush TL, et al. Identification of Cardiac Expression Pattern of Transient Receptor Potential Vanilloid Type 1 (TRPV1) Receptor using a Transgenic Reporter Mouse Model. Neurosci lett. 2020;737:135320. doi: 10.1016/j.neulet.2020.135320
   PubMed Web of Science ®Google Scholar
• Andrei SR, Sinharoy P, Bratz IN, et al. TRPA1 is functionally co-expressed with TRPV1 in cardiac muscle: co-localization at z-discs, costameres and intercalated discs. channels (Austin, Tex. Channels. 2016;10(5):395–409. doi: 10.1080/19336950.2016.1185579
   PubMed Web of Science ®Google Scholar
• Bizino MB, Jazet IM, Westenberg JJM, et al. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial. Cardiovasc Diabetol. 2019;18(1):55. doi: 10.1186/s12933-019-0857-6
   PubMed Web of Science ®Google Scholar
• Ching L-C, Chen C-Y, Su K-H, et al. Implication of AMP-activated protein kinase in transient receptor potential vanilloid type 1-mediated activation of endothelial nitric oxide synthase. molecular medicine (Cambridge, Mass. 2012;18(5):805–815. doi: 10.2119/molmed.2011.00461
   Google Scholar
• Wang Y, Cui L, Xu H, et al. TRPV1 agonism inhibits endothelial cell inflammation via activation of eNOS/NO pathway. Atherosclerosis. 2017;260:13–19. doi: 10.1016/j.atherosclerosis.2017.03.016
   PubMed Web of Science ®Google Scholar
• Ma L, Zhong J, Zhao Z, et al. Activation of TRPV1 reduces vascular lipid accumulation and attenuates atherosclerosis. Cardiovasc Res. 2011;92(3):504–513. doi: 10.1093/cvr/cvr245
   PubMed Web of Science ®Google Scholar
• Luo D, Li W, Xie C, et al. Capsaicin attenuates arterial calcification through promoting SIRT6-mediated deacetylation and degradation of Hif1α (hypoxic-inducible factor-1 alpha). Hypertension. 2022;79(5):906–917. Hypertension (Dallas, Tex. : 1979). doi: 10.1161/HYPERTENSIONAHA.121.18778
   PubMed Web of Science ®Google Scholar
• Parpaite T, Cardouat G, Mauroux M, et al. Effect of hypoxia on TRPV1 and TRPV4 channels in rat pulmonary arterial smooth muscle cells. Pflugers Archiv. Pflugers Arch - Eur J Physiol. 2016;468(1):111–130. doi: 10.1007/s00424-015-1704-6
   PubMed Web of Science ®Google Scholar
• Sun Z, Han J, Zhao W, et al. TRPV1 activation exacerbates hypoxia/reoxygenation-induced apoptosis in H9C2 cells via calcium overload and mitochondrial dysfunction. Int J Mol Sci. 2014;15(10):18362–18380. doi: 10.3390/ijms151018362
   PubMed Web of Science ®Google Scholar
• Gao F, Liang Y, Wang X, et al. TRPV1 activation attenuates high-salt diet-induced cardiac hypertrophy and fibrosis through PPAR-δ upregulation. PPAR Res. 2014;2014:1–12. doi: 10.1155/2014/491963
   Web of Science ®Google Scholar
• Lang H, Li Q, Yu H, et al. Activation of TRPV1 attenuates high salt-induced cardiac hypertrophy through improvement of mitochondrial function. Br J Pharmacol. 2015;172(23):5548–5558. doi: 10.1111/bph.12987
   PubMed Web of Science ®Google Scholar
• Horton JS, Shiraishi T, Alfulaij N, et al. TRPV1 is a component of the atrial natriuretic signaling complex, and using orally delivered antagonists, presents a valid therapeutic target in the longitudinal reversal and treatment of cardiac hypertrophy and heart failure. Channels (Austin, Tex). 2019;13(1):1–16. doi: 10.1080/19336950.2018.1547611
   PubMed Web of Science ®Google Scholar
• Wei J, Lin J, Zhang J, et al. TRPV1 activation mitigates hypoxic injury in mouse cardiomyocytes by inducing autophagy through the AMPK signaling pathway. Am J Physiol Cell Physiol. 2020;318(5):C1018–C1029. doi: 10.1152/ajpcell.00161.2019
   PubMed Web of Science ®Google Scholar
• Zhong B, Rubinstein J, Ma S, et al. Genetic ablation of TRPV1 exacerbates pressure overload-induced cardiac hypertrophy. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2018;99:261–270. doi: 10.1016/j.biopha.2018.01.065
   PubMed Web of Science ®Google Scholar
• Scotland RS, Chauhan S, Davis C, et al. Vanilloid receptor TRPV1, sensory C-fibers, and vascular autoregulation: a novel mechanism involved in myogenic constriction. Circ Res. 2004;95(10):1027–1034. doi: 10.1161/01.RES.0000148633.93110.24
   PubMed Web of Science ®Google Scholar
• Hoover DB. Effects of capsaicin on release of substance P-like immunoreactivity and physiological parameters in isolated perfused guinea-pig heart. Eur J Pharmacol. 1987;141(3):489–492. doi: 10.1016/0014-2999(87)90571-1
   PubMed Web of Science ®Google Scholar
• Manzini S, Perretti F, de Benedetti L, et al. A comparison of bradykinin- and capsaicin-induced myocardial and coronary effects in isolated perfused heart of guinea-pig: involvement of substance P and calcitonin gene-related peptide release. Br J Pharmacol. 1989;97(2):303–312. doi: 10.1111/j.1476-5381.1989.tb11955.x
   PubMed Web of Science ®Google Scholar
• Szabados T, Gömöri K, Pálvölgyi L, et al. Capsaicin-Sensitive sensory nerves and the TRPV1 ion channel in cardiac Physiology and pathologies. Int J Mol Sci. 2020;21(12):4472. doi: 10.3390/ijms21124472
   PubMed Web of Science ®Google Scholar
• Li J, Zhao H, Supowit SC, et al. Activation of the renin–angiotensin system in α-calcitonin gene-related peptide/calcitonin gene knockout mice. J Hypertens. 2004;22(7):1345–1349. doi: 10.1097/01.hjh.0000125409.50839.f1
   PubMed Web of Science ®Google Scholar
• Wang L, Wang DH. TRPV1 gene knockout impairs postischemic recovery in isolated perfused heart in mice. Circulation. 2005;112(23):3617–3623. doi: 10.1161/CIRCULATIONAHA.105.556274
   PubMed Web of Science ®Google Scholar
• Xiong S, Wang P, Ma L, et al. Ameliorating endothelial mitochondrial dysfunction restores coronary function via Transient receptor potential vanilloid 1–mediated protein kinase A/Uncoupling protein 2 pathway. Hypertension (Dallas, Tex. : 1979). 2016;67(2):451–460. doi: 10.1161/HYPERTENSIONAHA.115.06223
   Google Scholar
• McCarty MF, DiNicolantonio JJ, O’Keefe JH. Capsaicin may have important potential for promoting vascular and metabolic health. Open Heart. 2015;2(1):e000262. doi: 10.1136/openhrt-2015-000262
   PubMed Web of Science ®Google Scholar
• Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Investig. 1980;65(1):128–135. doi: 10.1172/JCI109642
   PubMed Web of Science ®Google Scholar
• Chen Y, Saari JT, Kang YJ. Weak antioxidant defenses make the heart a target for damage in copper-deficient rats. Free Radic Biol Med. 1994;17(6):529–536. doi: 10.1016/0891-5849(94)90092-2
   PubMed Web of Science ®Google Scholar
• Huynh K, Bernardo BC, McMullen JR, et al. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. Pharmacol Ther. 2014;142(3):375–415. doi: 10.1016/j.pharmthera.2014.01.003
   PubMed Web of Science ®Google Scholar
• Faria A, Persaud SJ. Cardiac oxidative stress in diabetes: mechanisms and therapeutic potential. Pharmacol Ther. 2017;172:50–62. doi: 10.1016/j.pharmthera.2016.11.013
   PubMed Web of Science ®Google Scholar
• Hamblin M, Friedman DB, Hill S, et al. Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. J Mol Cell Cardiol. 2007;42(4):884–895. doi: 10.1016/j.yjmcc.2006.12.018
   PubMed Web of Science ®Google Scholar
• Di Filippo C, Marfella R, Cuzzocrea S, et al. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes. 2005;54(3):803–810. doi: 10.2337/diabetes.54.3.803
   PubMed Web of Science ®Google Scholar
• D’Amario D, Migliaro S, Borovac JA, et al. Microvascular dysfunction in heart failure with preserved ejection fraction. Front Physiol. 2019;10:1347. doi: 10.3389/fphys.2019.01347
   PubMed Web of Science ®Google Scholar
• Gambardella J, Sorriento D, Ciccarelli M, et al. Functional role of mitochondria in Arrhythmogenesis. Adv Exp Med Biol. 2017;982:191–202.
   PubMed Web of Science ®Google Scholar
• Aboumsallem JP, Muthuramu I, Mishra M, et al. Effective treatment of diabetic cardiomyopathy and heart failure with reconstituted HDL (Milano) in mice. Int J Mol Sci. 2019;20(6):1273. doi: 10.3390/ijms20061273
   PubMed Web of Science ®Google Scholar
• Moukdar F, Robidoux J, Lyght O, et al. Reduced antioxidant capacity and diet-induced atherosclerosis in uncoupling protein-2-deficient mice. J Lipid Res. 2009;50(1):59–70. doi: 10.1194/jlr.M800273-JLR200
   PubMed Web of Science ®Google Scholar
• Tian XY, Wong WT, Xu A, et al. Uncoupling protein-2 protects endothelial function in diet-induced obese mice. Circ Res. 2012;110(9):1211–1216. doi: 10.1161/CIRCRESAHA.111.262170
   PubMed Web of Science ®Google Scholar
• Dhamrait SS, et al. ?Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. Eur Heart J. 2004;25(6):468–475. doi: 10.1016/j.ehj.2004.01.007
   PubMed Web of Science ®Google Scholar
• Li L, Chen J, Ni Y, et al. TRPV1 activation prevents nonalcoholic fatty liver through UCP2 upregulation in mice. Pflugers Archiv. European J Physiology. 2012;463(5):727–732. doi: 10.1007/s00424-012-1078-y
   Google Scholar
• Lee M-S, Kim, CT, Kim, IH, et al. Effects of capsaicin on lipid catabolism in 3T3-L1 adipocytes. Phytother Res. 2011;25(6):935–939. doi: 10.1002/ptr.3339
   PubMed Web of Science ®Google Scholar
• Sun J, Pu Y, Wang P, et al. TRPV1-mediated UCP2 upregulation ameliorates hyperglycemia-induced endothelial dysfunction. Cardiovasc Diabetol. 2013;12(1):69. doi: 10.1186/1475-2840-12-69
   PubMedGoogle Scholar
• Chen J, Zhang Z, Cai L. Diabetic cardiomyopathy and its prevention by nrf2: current status. Diabetes & Metabolism Journal. 2014;38(5):337–345. doi: 10.4093/dmj.2014.38.5.337
   PubMedGoogle Scholar
• He X, Kan H, Cai L, et al. Nrf2 is critical in defense against high glucose-induced oxidative damage in cardiomyocytes. J Mol Cell Cardiol. 2009;46(1):47–58. doi: 10.1016/j.yjmcc.2008.10.007
   PubMed Web of Science ®Google Scholar
• Tan Y, Ichikawa T, Li J, et al. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress–induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes. 2011;60(2):625–633. doi: 10.2337/db10-1164
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun W, Du B, et al. Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-κB. Am J Physiol Heart Circ Physiol. 2013;304(4):H567–H578. doi: 10.1152/ajpheart.00650.2012
   PubMed Web of Science ®Google Scholar
• Velmurugan GV, Sundaresan NR, Gupta MP, et al. Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes. Cardiovasc Res. 2013;100(1):143–150. doi: 10.1093/cvr/cvt125
   PubMed Web of Science ®Google Scholar
• Xu Z, Wei Y, Gong J, et al. NRF2 plays a protective role in diabetic retinopathy in mice. Diabetologia. 2014;57(1):204–213. doi: 10.1007/s00125-013-3093-8
   PubMed Web of Science ®Google Scholar
• Lv Z, Xu X, Sun Z, et al. TRPV1 alleviates osteoarthritis by inhibiting M1 macrophage polarization via Ca2+/CaMKII/Nrf2 signaling pathway. Cell Death Dis. 2021;12(6):504. doi: 10.1038/s41419-021-03792-8
   PubMed Web of Science ®Google Scholar
• Flammer AJ, Anderson T, Celermajer DS, et al. The assessment of endothelial function: from research into clinical practice. Circulation. Circulation. 2012;126(6):753–767. doi: 10.1161/CIRCULATIONAHA.112.093245
   PubMed Web of Science ®Google Scholar
• Kitta Y, Obata J-E, Nakamura T, et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol. 2009;53(4):323–330. doi: 10.1016/j.jacc.2008.08.074
   PubMed Web of Science ®Google Scholar
• Moraes RDA, Webb RC, Silva DF. Vascular dysfunction in diabetes and obesity: focus on TRP channels. Front Physiol. 2021;12:645109. doi: 10.3389/fphys.2021.645109
   PubMed Web of Science ®Google Scholar
• Li X, Hou J, Du J, et al. Potential Protective Mechanism in the Cardiac Microvascular Injury. Hypertension. 2018;72(1):116–127. Hypertension (Dallas, Tex. : 1979). doi: 10.1161/HYPERTENSIONAHA.118.11035
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang X, Guo L, et al. TRPV1 activation inhibits phenotypic switching and oxidative stress in vascular smooth muscle cells by upregulating PPARα. Biochem Biophys Res Commun. 2021;545:157–163. doi: 10.1016/j.bbrc.2021.01.072
   PubMed Web of Science ®Google Scholar
• Zhu S-L, Wang M-L, He Y-T, et al. Capsaicin ameliorates intermittent high glucose-mediated endothelial senescence via the TRPV1/SIRT1 pathway. Phytomedicine. 2022;100:154081. doi: 10.1016/j.phymed.2022.154081
   PubMed Web of Science ®Google Scholar
• Frieler RA, Mortensen RM. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation. 2015;131(11):1019–1030. doi: 10.1161/CIRCULATIONAHA.114.008788
   PubMed Web of Science ®Google Scholar
• Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116(7):1254–1268. doi: 10.1161/CIRCRESAHA.116.302317
   PubMed Web of Science ®Google Scholar
• Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119(1):91–112. doi: 10.1161/CIRCRESAHA.116.303577
   PubMed Web of Science ®Google Scholar
• Yang J, Park Y, Zhang H, et al. Feed-forward signaling of TNF-α and NF-κB via IKK-β pathway contributes to insulin resistance and coronary arteriolar dysfunction in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2009;296(6):H1850–H1858. doi: 10.1152/ajpheart.01199.2008
   PubMed Web of Science ®Google Scholar
• Mann DL, Kirschenbaum L. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res. 2011;108(9):1133–1145. doi: 10.1161/CIRCRESAHA.110.226936
   PubMed Web of Science ®Google Scholar
• Sciarretta S, Paneni F, Palano F, et al. Role of the renin–angiotensin–aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction. Clinical Science (London, England). 2009;116(6):467–477. doi: 10.1042/CS20080390
   Google Scholar
• Yan SF, Ramasamy R, Naka Y, et al. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res. 2003;93(12):1159–1169. doi: 10.1161/01.RES.0000103862.26506.3D
   PubMed Web of Science ®Google Scholar
• Westermann D, Walther T, Savvatis K, et al. Gene deletion of the kinin receptor B1 attenuates cardiac inflammation and fibrosis during the development of experimental diabetic cardiomyopathy. Diabetes. 2009;58(6):1373–1381. doi: 10.2337/db08-0329
   PubMed Web of Science ®Google Scholar
• Fernandes ES, Liang L, Smillie S-J, et al. TRPV1 deletion enhances local inflammation and accelerates the onset of systemic inflammatory response syndrome. Journal Of Immunology (Baltimore, Md). 2012;188(11):5741–5751. doi: 10.4049/jimmunol.1102147
   PubMed Web of Science ®Google Scholar
• Ching L-C, Kou YR, Shyue S-K, et al. Molecular mechanisms of activation of endothelial nitric oxide synthase mediated by transient receptor potential vanilloid type 1. Cardiovasc Res. 2011;91(3):492–501. doi: 10.1093/cvr/cvr104
   PubMed Web of Science ®Google Scholar
• Singh S, Natarajan K, Aggarwal BB. Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a potent inhibitor of nuclear transcription factor-kappa B activation by diverse agents. J Immun (Baltimore. 1996;157(10):4412–4420. Md. : 1950). doi: 10.4049/jimmunol.157.10.4412
   PubMed Web of Science ®Google Scholar
• Sancho R, Macho A, de La Vega L, et al. Immunosuppressive activity of endovanilloids: N -arachidonoyl-dopamine inhibits activation of the NF-κB, NFAT, and activator protein 1 signaling pathways. Journal Of Immunology (Baltimore, Md). 2004;172(4):2341–2351. doi: 10.4049/jimmunol.172.4.2341
   PubMed Web of Science ®Google Scholar
• Huang W, Rubinstein J, Prieto AR, et al. Transient receptor potential vanilloid gene deletion exacerbates inflammation and atypical cardiac remodeling after myocardial infarction. Hypertension. 2009;53(2):243–250. Hypertension (Dallas, Tex. : 1979). doi: 10.1161/HYPERTENSIONAHA.108.118349
   PubMed Web of Science ®Google Scholar
• Jia G, Habibi J, DeMarco VG, et al. Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension. 2015;66(6):1159–1167. Hypertension (Dallas, Tex.: 1979). doi: 10.1161/HYPERTENSIONAHA.115.06015
   PubMed Web of Science ®Google Scholar
• Ururahy MAG, Loureiro MB, Freire-Neto FP, et al. Increased TLR2 expression in patients with type 1 diabetes: evidenced risk of microalbuminuria. Pediatr Diabetes. 2012;13(2):147–154. doi: 10.1111/j.1399-5448.2011.00794.x
   PubMed Web of Science ®Google Scholar
• Lv Z, Xu X, Sun Z, et al. TRPV1 alleviates osteoarthritis by inhibiting M1 macrophage polarization via Ca/CaMKII/Nrf2 signaling pathway. Cell Death Dis. 2021;12(6):504. doi: 10.1038/s41419-021-03792-8
   PubMed Web of Science ®Google Scholar
• Zhao J-F, Ching L-C, Kou YR, et al. Activation of TRPV1 prevents OxLDL-induced lipid accumulation and TNF-α-induced inflammation in macrophages: role of liver X receptor α. Mediators Inflamm. 2013;2013:1–14. doi: 10.1155/2013/925171
   Web of Science ®Google Scholar
• Anderson EJ, Kypson AP, Rodriguez E, et al. Substrate-specific derangements in mitochondrial metabolism and redox balance in the atrium of the type 2 diabetic human heart. J Am Coll Cardiol. 2009;54(20):1891–1898. doi: 10.1016/j.jacc.2009.07.031
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Rodriguez E, Anderson CA, et al. Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways. Am J Physiol Heart Circ Physiol. 2011;300(1):H118–H124. doi: 10.1152/ajpheart.00932.2010
   PubMed Web of Science ®Google Scholar
• Kim J-A, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res. 2008;102(4):401–414. doi: 10.1161/CIRCRESAHA.107.165472
   PubMed Web of Science ®Google Scholar
• Luo Z, Ma L, Zhao Z, et al. TRPV1 activation improves exercise endurance and energy metabolism through PGC-1α upregulation in mice. Cell Res. 2012;22(3):551–564. doi: 10.1038/cr.2011.205
   PubMed Web of Science ®Google Scholar
• Wang Y-X, Zhang C-L, Yu RT, et al. Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol. 2004;2(10):e294. doi: 10.1371/journal.pbio.0020294
   PubMed Web of Science ®Google Scholar
• Joyner MJ, Coyle EF. Endurance exercise performance: the physiology of champions. Journal Of Physiology. 2008;586(1):35–44. doi: 10.1113/jphysiol.2007.143834
   PubMed Web of Science ®Google Scholar
• Wu S, Lu Q, Ding Y, et al. Hyperglycemia-Driven inhibition of AMP-Activated protein kinase α2 induces diabetic cardiomyopathy by promoting mitochondria-associated endoplasmic reticulum membranes in vivo. Circulation. 2019;139(16):1913–1936. doi: 10.1161/CIRCULATIONAHA.118.033552
   PubMed Web of Science ®Google Scholar
• Wu S, Lu Q, Wang Q, et al. Binding of FUN14 domain containing 1 with inositol 1,4,5-trisphosphate receptor in mitochondria-associated endoplasmic reticulum Membranes Maintains mitochondrial Dynamics and function in hearts in vivo. Circulation. 2017;136(23):2248–2266. doi: 10.1161/CIRCULATIONAHA.117.030235
   PubMed Web of Science ®Google Scholar
• Wei X, Wei X, Lu Z, et al. Activation of TRPV1 channel antagonizes diabetic nephropathy through inhibiting endoplasmic reticulum-mitochondria contact in podocytes. Metabolism. 2020;105:154182. doi: 10.1016/j.metabol.2020.154182
   PubMed Web of Science ®Google Scholar
• Shimizu M, Umeda K, Sugihara N, et al. Collagen remodelling in myocardia of patients with diabetes. J Clin Pathol. 1993;46(1):32–36. doi: 10.1136/jcp.46.1.32
   PubMed Web of Science ®Google Scholar
• Abed HS, Samuel CS, Lau DH, et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm. 2013;10(1):90–100. doi: 10.1016/j.hrthm.2012.08.043
   PubMed Web of Science ®Google Scholar
• Gao Y, Kang L, Li C, et al. Resveratrol ameliorates diabetes-induced cardiac dysfunction through AT1R-ERK/p38 MAPK signaling pathway. Cardiovasc Toxicol. 2016;16(2):130–137. doi: 10.1007/s12012-015-9321-3
   PubMed Web of Science ®Google Scholar
• Suematsu Y, Miura S-I, Goto M, et al. LCZ696 , an angiotensin receptor–neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. European J Heart Fail. 2016;18(4):386–393. doi: 10.1002/ejhf.474
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. The role of transforming growth factor (TGF)-β in the infarcted myocardium. J Thoracic Dis. 2017;9(Suppl 1):S52–S63. doi: 10.21037/jtd.2016.11.19
   PubMedGoogle Scholar
• Travers JG, Kamal FA, Robbins J, et al. Cardiac fibrosis: the fibroblast awakens. Circ Res. 2016;118(6):1021–1040. doi: 10.1161/CIRCRESAHA.115.306565
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang Y, Li D, et al. Transgenic overexpression of transient receptor potential vanilloid subtype 1 attenuates isoproterenol-induced myocardial fibrosis in mice. Int J Mol Med. 2016;38(2):601–609. doi: 10.3892/ijmm.2016.2648
   PubMed Web of Science ®Google Scholar
• An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2006;291(4):H1489–H1506. doi: 10.1152/ajpheart.00278.2006
   PubMed Web of Science ®Google Scholar
• Rijzewijk LJ, van der Meer RW, Lamb HJ, et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J Am Coll Cardiol. 2009;54(16):1524–1532. doi: 10.1016/j.jacc.2009.04.074
   PubMed Web of Science ®Google Scholar
• Ghosh S, An D, Pulinilkunnil T, et al. Role of dietary fatty acids and acute hyperglycemia in modulating cardiac cell death. Calif.) (Burbank, Los Angeles County. Nutrition. 2004;20(10):916–923. doi: 10.1016/j.nut.2004.06.013
   PubMed Web of Science ®Google Scholar
• Buchanan J, Mazumder PK, Hu P, et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology. 2005;146(12):5341–5349. doi: 10.1210/en.2005-0938
   PubMed Web of Science ®Google Scholar
• Aasum E, Hafstad AD, Severson DL, et al. Age-dependent changes in metabolism, contractile function, and ischemic sensitivity in hearts from db/db mice. Diabetes. 2003;52(2):434–441. doi: 10.2337/diabetes.52.2.434
   PubMed Web of Science ®Google Scholar
• Panchal SK, Bliss E, Brown L. Capsaicin in Metabolic Syndrome. Nutrients. 2018;10(5):630. doi: 10.3390/nu10050630
   PubMed Web of Science ®Google Scholar
• Akiba Y, Kato S, Katsube K-I, et al. Transient receptor potential vanilloid subfamily 1 expressed in pancreatic islet β cells modulates insulin secretion in rats. Biochem Biophys Res Commun. 2004;321(1):219–225. doi: 10.1016/j.bbrc.2004.06.149
   PubMed Web of Science ®Google Scholar
• Tsui H, Razavi R, Chan Y, et al. ‘Sensing’ autoimmunity in type 1 diabetes. Trends Mol Med. 2007;13(10):405–413. doi: 10.1016/j.molmed.2007.07.006
   PubMed Web of Science ®Google Scholar
• Razavi R, Chan Y, Afifiyan FN, et al. TRPV1+ Sensory Neurons Control β Cell Stress and Islet Inflammation in Autoimmune Diabetes. Cell. 2006;127(6):1123–1135. doi: 10.1016/j.cell.2006.10.038
   PubMed Web of Science ®Google Scholar
• Zhong B, Ma S, Wang DH. TRPV1 Mediates Glucose-induced Insulin Secretion Through Releasing Neuropeptides. Vivo (Athens, Greece). 2019;33(5):1431–1437. doi: 10.21873/invivo.11621
   PubMed Web of Science ®Google Scholar
• Wang P, Yan Z, Zhong J, et al. Transient receptor potential vanilloid 1 activation enhances gut glucagon-like peptide-1 secretion and improves glucose homeostasis. Diabetes. 2012;61(8):2155–2165. doi: 10.2337/db11-1503
   PubMed Web of Science ®Google Scholar
• Parlevliet ET, de Leeuw van Weenen JE, Romijn JA, et al. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. Am J Physiol Endocrinol Metab. 2010;299(2):E318–E324. doi: 10.1152/ajpendo.00191.2010
   PubMed Web of Science ®Google Scholar
• Borghetti G, von Lewinski D, Eaton DM, et al. Diabetic cardiomyopathy: Current and future therapies. Beyond glycemic control. Front Physiol. 2018;9:1514. doi: 10.3389/fphys.2018.01514
   PubMed Web of Science ®Google Scholar
• Stratton IM, Wei X, Lu Z, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405–412. doi: 10.1136/bmj.321.7258.405
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of Care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S140–S157. doi: 10.2337/dc23-S009
   PubMedGoogle Scholar
• Chen YH, Feng B, Chen ZW. Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis. Experimental And Clinical Endocrinology & Diabetes: Official Journal, German Society Of Endocrinology [And] German Diabetes Association. 2012;120(2):116–120. doi: 10.1055/s-0031-1297968
   PubMed Web of Science ®Google Scholar
• Varzideh F, Kansakar U, Santulli G. SGLT2 inhibitors in cardiovascular medicine. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):e67–e68. doi: 10.1093/ehjcvp/pvab039
   PubMed Web of Science ®Google Scholar
• Ng K-M, Lau Y-M, Dhandhania V, et al. Empagliflozin Ammeliorates High Glucose Induced-Cardiac Dysfuntion in Human iPSC-Derived Cardiomyocytes. Sci Rep. 2018;8(1):14872. doi: 10.1038/s41598-018-33293-2
   PubMedGoogle Scholar
• Wang D, Jiang L, Feng B, et al. Protective effects of glucagon-like peptide-1 on cardiac remodeling by inhibiting oxidative stress through mammalian target of rapamycin complex 1/p70 ribosomal protein S6 kinase pathway in diabetes mellitus. J of Diabetes Invest. 2020;11(1):39–51. doi: 10.1111/jdi.13098
   PubMed Web of Science ®Google Scholar
• Liu J, Liu Y, Chen L, et al. Glucagon-like peptide-1 Analog Liraglutide protects against diabetic cardiomyopathy by the inhibition of the endoplasmic reticulum stress pathway. J Diabetes Res. 2013;2013:1–8. doi: 10.1155/2013/630537
   Web of Science ®Google Scholar
• Arow M, Waldman M, Yadin D, et al. Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy. Cardiovasc Diabetol. 2020;19(1):7. doi: 10.1186/s12933-019-0980-4
   PubMed Web of Science ®Google Scholar
• Steven S, Oelze M, Hanf A, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370–385. doi: 10.1016/j.redox.2017.06.009
   PubMed Web of Science ®Google Scholar
• Croteau D, Baka T, Young S, et al. SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2023;160:114310. doi: 10.1016/j.biopha.2023.114310
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827
   PubMed Web of Science ®Google Scholar
• Lambadiari V, Pavlidis G, Kousathana F, et al. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):8. doi: 10.1186/s12933-017-0646-z
   PubMedGoogle Scholar
• Otto M, Bucher C, Liu W, et al. 12(S)-HETE mediates diabetes-induced endothelial dysfunction by activating intracellular endothelial cell TRPV1. J Clin Investig. 2020;130(9):4999–5010. doi: 10.1172/JCI136621
   PubMed Web of Science ®Google Scholar
• Otto M, Brabenec L, Müller M, et al. Development of heart failure with preserved ejection fraction in type 2 diabetic mice is ameliorated by preserving vascular function. Life Sci. 2021;284:119925. doi: 10.1016/j.lfs.2021.119925
   PubMed Web of Science ®Google Scholar
• Hennessy E, Rakovac Tisdall A, Murphy N, et al. Elevated 12-hydroxyeicosatetraenoic acid (12-HETE) levels in serum of individuals with newly diagnosed type 1 diabetes. Diabet Med. 2017;34(2):292–294. doi: 10.1111/dme.13177
   PubMed Web of Science ®Google Scholar
• Zhang HJ, Sun CH, Kuang HY, et al. 12S-hydroxyeicosatetraenoic acid levels link to coronary artery disease in type 2 diabetic patients. J Endocrinol Invest. 2013;36(6):385–389. doi: 10.3275/8654
   PubMed Web of Science ®Google Scholar
• Antonipillai I, Nadler, JE, Vu, EJ, et al. A 12-lipoxygenase product, 12-hydroxyeicosatetraenoic acid, is increased in diabetics with incipient and early renal disease. J Clin Endocrinol Metab. 1996;81(5):1940–1945. doi: 10.1210/jc.81.5.1940
   PubMed Web of Science ®Google Scholar
• Fernandes ES, Fernandes MA, Keeble JE. The functions of TRPA1 and TRPV1: moving away from sensory nerves. Br J Pharmacol. 2012;166(2):510–521. doi: 10.1111/j.1476-5381.2012.01851.x
   PubMed Web of Science ®Google Scholar